Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2024
Li X-Q, Yamazaki T, He T, Alam MMasud, Liu J, Trivett AL, Sveinbjørnsson B, Rekdal Ø, Galluzzi L, Oppenheim JJ et al..  2024.  LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells.. Front Immunol. 15:1332922.
Chaudhry F, Kim TWan, Elemento O, Betel D.  2024.  Machine learning analysis of population-wide plasma proteins identifies hormonal biomarkers of Parkinson's Disease.. medRxiv.
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ et al..  2024.  Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).. Eur Urol.
Montrose DC, Saha S, Galluzzi L.  2024.  Metabolic regulation of the mitochondrial immune checkpoint.. Oncoimmunology. 13(1):2394247.
Pandey RS, Arnold M, Batra R, Krumsiek J, Kotredes KP, Garceau D, Williams H, Sasner M, Howell GR, Kaddurah-Daouk R et al..  2024.  Metabolomics profiling reveals distinct, sex-specific signatures in serum and brain metabolomes in mouse models of Alzheimer's disease.. Alzheimers Dement.
Guilbaud E, Galluzzi L.  2024.  A mitochondrial checkpoint to NF-κB signaling.. Cell Death Dis. 15(7):477.
Galassi C, Klapp V, Yamazaki T, Galluzzi L.  2024.  Molecular determinants of immunogenic cell death elicited by radiation therapy.. Immunol Rev. 321(1):20-32.
Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, Beja K, Mizuno K, Ku S, Fazli L et al..  2024.  Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.. J Natl Cancer Inst. 116(1):115-126.
Beltrán-Visiedo M, Balachandran S, Galluzzi L.  2024.  MRE11 mobilizes CGAS and drives ZBP1-dependent necroptosis.. Cell Res.
Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KEnnu, Hanna S, Askan G, Burman J et al..  2024.  Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer.. Nat Med.
Liu J, Cao S, Imbach KJ, Gritsenko MA, Lih T-SM, Kyle JE, Yaron-Barir TM, Binder ZA, Li Y, Strunilin I et al..  2024.  Multi-scale signaling and tumor evolution in high-grade gliomas.. Cancer Cell. 42(7):1217-1238.e19.
Paul S, Sarraf SA, Nam KHong, Zavar L, DeFoor N, Biswas SRanjan, Fritsch LE, Yaron TM, Johnson JL, Huntsman EM et al..  2024.  NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis.. J Cell Biol. 223(2)
Suhre K, Venkataraman GRam, Guturu H, Halama A, Stephan N, Thareja G, Sarwath H, Motamedchaboki K, Donovan MKR, Siddiqui A et al..  2024.  Nanoparticle enrichment mass-spectrometry proteomics identifies protein-altering variants for precise pQTL mapping.. Nat Commun. 15(1):989.
Hissong E, Assaad MAl, Bal M, Reed KA, Fornelli A, Levine MF, Gundem G, Semaan A, Orr CE, Sakhadeo U et al..  2024.  NIPBL::NACC1 Fusion Hepatic Carcinoma.. Am J Surg Pathol. 48(2):183-193.
Franceschini GMarco, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S-Y, Sigouros M, Rothmann E, Alonso A, Benelli M et al..  2024.  Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.. Cancer Discov. 14(3):424-445.
Stern LJ, Clement C, Galluzzi L, Santambrogio L.  2024.  Non-mutational neoantigens in disease.. Nat Immunol. 25(1):29-40.
de la Mora JDelgado-, Assaad MAl, Quitian S, Levine MF, Deshpande A, Sigouros M, Manohar J, Medina-Martínez JS, Sboner A, Elemento O et al..  2024.  Novel structural variants that impact cell cycle genes are elucidated in metastatic gastrointestinal stromal tumors.. Pathol Res Pract. 266:155782.
Kudman S, Semaan A, Assaad MAl, Gogineni S, M Martin L, Mathew S, Elemento O, Wilkes DC, Mosquera JMiguel.  2024.  Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine.. Curr Protoc. 4(6):e1093.
Hanif SZ, Au CMCherie, Torregroza I, Jannath SY, Fabiha T, Bhinder B, Washburn M, Devost D, Liu S, Bhardwaj P et al..  2024.  The Orphan G Protein-Coupled Receptor GPR52 is a Novel Regulator of Breast Cancer Multicellular Organization.. bioRxiv.
Petralia F, Ma W, Yaron TM, Caruso FPia, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB et al..  2024.  Pan-cancer proteogenomics characterization of tumor immunity.. Cell. 187(5):1255-1277.e27.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Naulin F, Guilbaud E, Galluzzi L.  2024.  PARP7 and nucleic acid-driven oncosuppression.. Cell Mol Immunol.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Wu Y, Foollee A, Chan AY, Hille S, Hauke J, Challis MP, Johnson JL, Yaron TM, Mynard V, Aung OH et al..  2024.  Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon.. Nat Commun. 15(1):8390.
Glass J, Elemento O.  2024.  The power and perils of large language models in haematology.. Br J Haematol.